In the treatment of OA of the knee(s) GET BACK TO DOING MORE WITH PENNSAID

PENNSAID is the only topical NSAID proven to work on 2 of the main goals of knee OA treatment: reducing pain and improving physical function. Physical function is your ability to do everyday activities, such as getting in or out of the car, putting on your socks, and walking up stairs.

Pennsaid can help you control your knee OA symptoms so you can get back to your daily routine.

PENNSAID gives you a localized approach which may help you improve your physical function compared with people who took a placebo liquid solution.

Studies showed that people who took PENNSAID had less knee pain and improved physical function compared to people who took a placebo liquid solution.

TREAT KNEE OA WHERE IT STARTS.

The unique formulation of PENNSAID contains a penetration enhancer.

Learn more about How to apply PENNSAID.

If you have questions about PENNSAID, talk to your doctor, or read Frequently asked questions.

Altman RD. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care. 2009;15:S236-S243. Arthritis Foundation. All about Osteoarthritis. http://www.arthritistoday.org. Accessed January 6, 2011. Arthritis Foundation. NSAIDs. Arthritis Today Drug Guide. http://www.arthritistoday.org/treatments/drug‑guide/types‑of‑drugs/drug‑guide‑nsaids.php. Accessed January 6, 2011. Arthritis Foundation. NSAIDs. Who gets osteoarthritis. http://www.arthritis.org/who‑gets‑osteoarthritis.php. Accessed January 6, 2011. Arthrotec (diclofenac sodium/misoprostol) Tablets USP [prescribing information]. New York, NY: G.D. Searle LLC, Division of Pfizer. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840. Diclofenac sodium delayed release tablets USP [prescribing information]. Corona, CA: Watson Laboratories, Inc. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. Br Med J. 1995;311:22-26. Heyneman CW, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000;60:555-574. Notman R, Noro M, O’Malley B, Anwar J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. J Am Chem Soc. 2006;128:13982-13983. PENNSAID [package insert]. Mississauga, Ontario:Nuvo Research, Inc.; 2010.

INDICATION
PENNSAID® is a nonsteroidal anti-inflammatory drug (NSAID) used for treating the signs and symptoms of osteoarthritis of the knee(s).

IMPORTANT RISK INFORMATION

WARNING: CARDIOVASCULAR (CV) AND GASTROINTESTINAL (GI) RISK
    Cardiovascular Risk
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious blood clots in the heart, or cause a heart attack or stroke. These risks can cause death. The risk may increase the longer NSAIDs are used. Patients who have heart disease or are at risk for heart disease may be at greater risk
  • Do not use PENNSAID in patients who are in the hospital for heart bypass surgery grafts
    Gastrointestinal Risk
  • NSAIDs cause an increased risk of serious stomach problems or problems in the intestines. Patients could bleed or develop a hole in their stomach or intestines. All of these problems can cause death. These problems can happen at any time with no warning when using NSAIDs. Older patients are at greater risk for these problems

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG.
PENNSAID is a registered trademark of Nuvo Research Inc. Other brands are trademarks of their respective owners. © 2011 Covidien